HK1218621A1 - 用於治疗慢性炎症和炎性疾病的组合物及方法 - Google Patents

用於治疗慢性炎症和炎性疾病的组合物及方法 Download PDF

Info

Publication number
HK1218621A1
HK1218621A1 HK16106607.4A HK16106607A HK1218621A1 HK 1218621 A1 HK1218621 A1 HK 1218621A1 HK 16106607 A HK16106607 A HK 16106607A HK 1218621 A1 HK1218621 A1 HK 1218621A1
Authority
HK
Hong Kong
Prior art keywords
methods
chronic inflammation
compositions
inflammatory diseases
treating chronic
Prior art date
Application number
HK16106607.4A
Other languages
English (en)
Chinese (zh)
Inventor
Robin Mark Bannister
John Brew
Wilson CAPARRÓS-WANDERLEY
Suzanne Jane Dilly
Olga Pleguezuelos Mateo
Gregory Alan Stoloff
Original Assignee
Infirst Healthcare Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Infirst Healthcare Limited filed Critical Infirst Healthcare Limited
Publication of HK1218621A1 publication Critical patent/HK1218621A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK16106607.4A 2013-02-04 2014-01-14 用於治疗慢性炎症和炎性疾病的组合物及方法 HK1218621A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361752309P 2013-02-04 2013-02-04
US201361752309P 2013-02-04
PCT/EP2014/050627 WO2014117999A1 (en) 2013-02-04 2014-01-14 Compositions and methods for treating chronic inflammation and inflammatory diseases

Publications (1)

Publication Number Publication Date
HK1218621A1 true HK1218621A1 (zh) 2017-03-03

Family

ID=50150686

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16106607.4A HK1218621A1 (zh) 2013-02-04 2014-01-14 用於治疗慢性炎症和炎性疾病的组合物及方法

Country Status (14)

Country Link
EP (1) EP2950821A1 (https=)
JP (1) JP6474352B2 (https=)
KR (1) KR20150129664A (https=)
CN (1) CN105120900A (https=)
AU (1) AU2014211715B2 (https=)
BR (1) BR112015015870B1 (https=)
CA (1) CA2898017A1 (https=)
HK (1) HK1218621A1 (https=)
IL (1) IL239920A0 (https=)
MX (1) MX366317B (https=)
RU (1) RU2680801C2 (https=)
SG (1) SG11201505243PA (https=)
WO (1) WO2014117999A1 (https=)
ZA (1) ZA201505006B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
EP3313519B1 (en) * 2015-06-29 2023-05-31 Children's Medical Center Corporation Jak-stat inhibitors for the treatment of congenital myopathies
CN108283637A (zh) * 2018-04-04 2018-07-17 无锡市儿童医院 辛伐他汀的应用
WO2019195943A1 (en) * 2018-04-13 2019-10-17 Urban Juve Provisions Inc. Cannabis root extract, method of manufacture, method of use
JP2022534783A (ja) * 2019-06-03 2022-08-03 イミュノルクス インターナショナル コーポレーション 疾患を処置するための天然痘ワクチン及び幹細胞
US20220378729A1 (en) * 2019-11-06 2022-12-01 Smartech Topical, Inc. Topical formulations of cyclooxygenase inhibitors and their use
RU2749857C1 (ru) * 2019-12-23 2021-06-17 Псарева Нелли Александровна Способ борьбы со средним и наружным отитом
RU2752764C1 (ru) * 2020-12-14 2021-08-03 Общество с ограниченной ответственностью "Тривиум-ХХI" (ООО "Тривиум-ХХI") Фармацевтическая композиция, обладающая противовоспалительным действием
EP4312978A2 (en) 2021-03-27 2024-02-07 TRX Biosciences Limited Compositions having improved bioavailability of therapeutics
RU2760220C1 (ru) * 2021-06-02 2021-11-22 Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт ревматологии имени В.А. Насоновой» (ФГБНУ НИИР им. В.А. Насоновой) Способ определения клинически значимой усталости у больного ревматоидным артритом на фоне 5-летней терапии базисными противовоспалительными препаратами или базисными противовоспалительными препаратами в комплексе с генно-инженерными биологическими препаратами и/или психофармакотерапией и сопутствующего расстройства тревожно-депрессивного спектра
WO2025122472A1 (en) * 2023-12-04 2025-06-12 Primus Pharmaceuticals, Inc. Emollient compositions comprising linoleic acid and conjugated linoleic acid and methods of use

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143934A (en) * 1990-11-21 1992-09-01 A/S Dumex (Dumex Ltd.) Method and composition for controlled delivery of biologically active agents
GB9613858D0 (en) * 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
ATE265847T1 (de) * 1997-07-29 2004-05-15 Upjohn Co Selbstemulgierbare formulierung enthaltend lipophile verbindungen
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB2331458B (en) * 1997-11-21 2002-07-31 Gursharan Singh Moonga Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
KR20020011985A (ko) * 1999-05-07 2002-02-09 파르마솔 게엠베하 액상 및 고체상 지질 혼합물에 기초한 지질입자들 및 그의제조방법
MXPA01011343A (es) * 1999-05-07 2002-06-04 Pharmasol Gmbh Particulas de lipidos a base de mezclas de lipidos liquidos y solidos asi como procedimiento para su produccion.
EP1183014B1 (en) * 1999-06-14 2003-10-08 Cosmo S.p.A. Controlled release and taste masking oral pharmaceutical compositions
US6455067B1 (en) * 2000-05-24 2002-09-24 Sang-A Pharmaceutical Co., Ltd. Transdermal patch for nonsteroidal antiinflammatory drug(s)
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
RU2319508C2 (ru) * 2003-07-31 2008-03-20 ФАРМАЦИЯ ЭНД АПДЖОН КОМПАНИ ЭлЭлСи Диспергируемый препарат противовоспалительного агента
MX2007006183A (es) * 2004-11-24 2007-09-11 Merck & Co Inc Formulaciones farmaceuticas liquidas y semisolidas para administracion oral de una amida sustituida.
US20060138059A1 (en) 2004-12-28 2006-06-29 Vair Larry L Jr Corona-treated polypropylene liquid filtration media
KR20080023677A (ko) * 2005-04-28 2008-03-14 갈레니카 테크놀로지 아베 지질상을 포함하는 약학적 투약 형태
US20070249725A1 (en) * 2006-02-17 2007-10-25 Hubbard David R Pharmaceutical formulations of sympathetic antagonist for the treatment of chronic muscle pain
GB0704846D0 (en) * 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
EP2310371B1 (fr) 2008-05-26 2013-05-15 Genfit Composés agonistes ppar, préparation et utilisations pour le traitement du diabète et/ou des dyslipidémies
WO2012104654A1 (en) * 2011-02-04 2012-08-09 Biocopea Limited Compositions and methods for treating cardiovascular diseases

Also Published As

Publication number Publication date
MX2015009058A (es) 2016-01-08
BR112015015870A8 (pt) 2018-01-16
AU2014211715B2 (en) 2016-08-25
EP2950821A1 (en) 2015-12-09
AU2014211715A1 (en) 2015-07-23
MX366317B (es) 2019-07-03
BR112015015870A2 (pt) 2017-07-11
SG11201505243PA (en) 2015-08-28
CA2898017A1 (en) 2014-08-07
JP2016506941A (ja) 2016-03-07
CN105120900A (zh) 2015-12-02
WO2014117999A1 (en) 2014-08-07
BR112015015870B1 (pt) 2022-09-27
ZA201505006B (en) 2016-03-30
JP6474352B2 (ja) 2019-02-27
IL239920A0 (en) 2015-08-31
RU2015137659A (ru) 2017-03-10
KR20150129664A (ko) 2015-11-20
RU2680801C2 (ru) 2019-02-27

Similar Documents

Publication Publication Date Title
HK1218621A1 (zh) 用於治疗慢性炎症和炎性疾病的组合物及方法
WO2012104655A3 (en) Compostions and methods for treating chronic inflammation and inflammatory diseases
HK1217650A1 (zh) 用於治疗剧痛的组合物及方法
IL267997A (en) Preparations, formulations and methods for treating eye diseases
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
WO2015077503A8 (en) Autotaxin inhibitor compounds
EP3052476A4 (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
EP2967049A4 (en) Methods, compounds, and compositions for the treatment of angiotensin-related diseases
EP3250578A4 (en) Oligosaccharide compositions for use in nutritional compositions, and methods of producing thereof
EP3035992A4 (en) Compositions, methods and systems for the treatment of cutaneous disorders
EP3098224A4 (en) Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease
WO2014159669A3 (en) Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions
WO2014121137A3 (en) Compositions and methods for the treatment of neurodegenerative and other diseases
EP3275450A4 (en) Pharmaceutical composition for preventing or treating inflammatory diseases, containinglactococcus chungangensis
EP3071214A4 (en) Salacia compositions, methods of treatment by their administration, and methods of their preparation
WO2017079403A3 (en) Polymeric nanoparticles
EP3037099A4 (en) Pharmaceutical composition, preparation method therefor and use thereof
EP3040337A4 (en) 2, 6-di-nitrogen-containing substituted purine derivative, and preparation method, pharmaceutical composition and use thereof
HK1223300A1 (zh) 皮质类固醇组合物
EP3038631A4 (en) Anti-inflammatory compositions, methods and uses thereof
EP3011336A4 (en) Methods, systems, and composition related to neural disorders
EP2994156A4 (en) Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity
EP2994147A4 (en) Compositions and methods for the treatment of tinnitus
PL2953656T3 (pl) Usieciowane pod wpływem światła pochodne kwasu hialuronowego oraz sposób ich wytwarzania i zastosowanie